Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
| العنوان: | Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series |
|---|---|
| المؤلفون: | Albert Lai, Benjamin M. Ellingson, Frances Chow, Matthew Ji, Richard M. Green, Phioanh L. Nghiemphu, Linda M. Liau, Sean T Pianka, Donna Molaie, Liang Yen Liu, Nhung T Nguyen, Timothy F. Cloughesy |
| المصدر: | CNS oncology, vol 8, iss 2 CNS Oncology |
| بيانات النشر: | Future Medicine Ltd, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Long Term Survivorship, recurrence, Bevacizumab, Angiogenesis Inhibitors, bevacizumab, Recurrent Glioma, California, Cohort Studies, Young Adult, Rare Diseases, glioma, Internal medicine, Glioma, medicine, Humans, Case Series, Survivors, Retrospective Studies, Aged, Cancer, relapse, Series (stratigraphy), business.industry, glioblastoma, Neurosciences, General Medicine, Middle Aged, medicine.disease, Brain Disorders, Large cohort, Brain Cancer, Neoplasm Recurrence, Treatment Outcome, Local, survivor, Female, long term, lipids (amino acids, peptides, and proteins), progression, Neoplasm Recurrence, Local, business, medicine.drug, Glioblastoma |
| الوصف: | Aim: Long-term survivors (LTS)after glioma recurrence while on bevacizumab (Bev)therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & methods: We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients. Results: Among 962 grade-IV,221 grade III, and214 grade II Bev-treated glioma patients, we identified 28 (2.9%),14 (6.3%) and8(3.7%)Bev-LTS patients, respectively. 45Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy.Conclusion: Our study shows that a small portion of grade-IV, -III,and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence. |
| وصف الملف: | application/pdf |
| تدمد: | 2045-0915 2045-0907 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1243c73b378956d92f23c0fb31636935Test https://doi.org/10.2217/cns-2019-0007Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1243c73b378956d92f23c0fb31636935 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20450915 20450907 |
|---|